Lebrikizumab

Eli Lilly's targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) approved by FDA for moderate-to-severe atopic dermatitis in adults and adolescents aged 12+ with at least 40kg body weight, not well controlled by topical therapies. Ebglyss, effective with or without topical corticosteroids, showed 38% of patients achieving clear or almost-clear skin at week 16 in ADvocate trials, compared to 12% with placebo.

Eli Lilly's atopic dermatitis drug, EBGLYSS, approved by FDA for adults and children 12+ weighing at least 88 lbs. Based on ADvocate 1, 2, and ADhere studies, EBGLYSS met primary endpoint at 16 weeks. Available in U.S. soon, already approved in Europe and Japan. Analysts bullish on LLY stock, with Strong Buy consensus rating and 12.6% upside potential.

Eli Lilly's Ebglyss (lebrikizumab-lbkz) receives FDA approval for treating moderate-to-severe atopic dermatitis in individuals aged 12+ weighing at least 40kg, not well controlled by topical therapies. Ebglyss, a targeted IL-13 inhibitor, offers a monthly maintenance injection with initial dosing and potential itch relief, based on ADvocate 1, 2, and ADhere studies. Common side effects include eye and eyelid inflammation, injection site reactions, and shingles. Lilly plans to commercialize Ebglyss in the US and offers support services for patient access.

Eli Lilly's EBGLYSS (lebrikizumab-lbkz) receives FDA approval for treating moderate-to-severe atopic dermatitis in adults and children aged 12+. The IL-13 inhibitor, designed for those unresponsive to topical treatments, can be used with or without corticosteroids. It starts with a 500mg dose at weeks 0 and 2, followed by 250mg every two weeks until week 16, then shifts to a monthly maintenance dose. Clinical trials ADvocate 1, 2, and ADhere supported the approval. Lilly plans to launch EBGLYSS in the US and offers patient support programs, including co-pay assistance. The treatment is also approved in the EU and Japan, with further market expansion planned for late 2024.

FDA approves EBGLYSS, a new biologic treatment for moderate-to-severe atopic dermatitis, offering significant skin clearance and itch relief within weeks, with long-lasting efficacy through monthly maintenance doses.

FDA approves Roche's Ocrevus Zunovo for MS and Eli Lilly's Ebglyss for eczema. Walgreens to pay $106.8 million for fraudulent billing. WHO supports Bavarian Nordic's mpox vaccine distribution in low-income countries.

FDA approves EBGLYSS, a targeted IL-13 inhibitor, for moderate-to-severe atopic dermatitis not controlled by topicals. EBGLYSS offers significant skin clearance in 4 weeks and itch relief in 2 weeks, with long-lasting efficacy through monthly maintenance doses.

Eli Lilly reports 38% of Ebglyss users achieved clear or almost-clear skin at 16 weeks, compared to 12% with placebo.

Eli Lilly announces FDA approval of EBGLYSS, an IL-13 inhibitor for moderate-to-severe atopic dermatitis in adults and children 12+ years old weighing at least 88 pounds, not well controlled by topical therapies.